The treatment, which will be sold under the name Onapgo, is essentially a subcutaneous – under the skin – device that allows for continuous infusion of the dopamine agonist apomorphine ...

Supernus will make ONAPGO available in the second quarter of 2025 with a support team of experts, including a robust nurse education program, and access support at launch. “Continuous ...

Please provide your email address to receive an email when new articles are posted on . Onapgo is the first subcutaneous apomorphine infusion device approved to treat motor fluctuations in ...

THURSDAY, Feb. 6, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only subcutaneous apomorphine infusion ...

Patients should receive training on the proper use of the delivery device prior to starting treatment. The Food and Drug Administration (FDA) has approved Onapgo™ (apomorphine hydrochloride [HCl ...

Sold as Onapgo, this device gives a steady dose of apomorphine – a medicine that helps people with Parkinson’s disease move more easily – under the skin to help manage movement issues and ...

The company launched ONAPGO, a subcutaneous apomorphine infusion device for advanced Parkinson’s disease, early in Q2. Initial physician response has been positive, with over 100 prescribers ...

ONAPGO, a subcutaneous infusion device, treats motor fluctuations in advanced Parkinson's disease and launches in the U.S. in 2025. Supernus Pharmaceuticals has announced the FDA approval of ...

Supernus Pharmaceuticals' ONAPGO for Parkinson’s Disease received FDA approval, providing a basis for optimism despite past regulatory challenges with SPN-830. The company is methodically ...

The drug/device combination product, known in development as SPN-830, will be commercialized under the brand name Onapgo. Supernus said Tuesday it plans to launch Onapgo in the second quarter of ...